This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gan, Y. Articles by Au, J. L-S. Search for Related Content PubMed PubMed Citation Articles by Gan, Y. Articles by Au, J. L-S.

Pharmacodynamics of Taxol in Human Head and Neck Tumors¹

Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy [Y. G., M. G. W., J. L-S. A.]; Division of Urology [M. G. W., J. L-S. A.] and Department of Otolaryngology [D. E. S.], College of Medicine; and Comprehensive Cancer Center [M. G. W., D. E. S., J. L-S. A.], The Ohio State University, Columbus, Ohio 43210

The pharmacodynamics of taxol in human head and neck squamous cell carcinoma were studied using histocultures of surgical specimens from patients (n = 22). Tumors were treated with taxol for 24 h. The inhibition of DNA synthesis was determined by 48 h cumulative bromodeoxyuridine (BrdUrd) incorporation. The induction of apoptosis was measured by morphological changes, in situ DNA end labeling, post-exonuclease III-BrdUrd labeling, and DNA fragmentation. Inhibition of the BrdUrd labeling index (LI) by taxol was incomplete, with 11 tumors showing a maximal inhibition (E_max) of 30–50% and the remaining 11 tumors showing an E_max of 50–80%. For both groups, the inhibition approached maximum values at 1 µM taxol concentration; an additional 10-fold increase in drug concentrations did not significantly enhance the inhibition. The taxol concentrations required for a 30% inhibition (IC₃₀) were 4.2 and 0.3 µM for the first and second groups, respectively. The IC₃₀ correlated with the E_max (r² = 0.39; P < 0.001). Taxol induced apoptosis in all tumors; 11 tumors showed a maximal fraction of apoptotic tumor cells between 3 and 10% and 11 tumors between 13 and 28%, whereas untreated controls showed a maximal apoptotic index of <1%. For individual tumors, the maximal apoptotic index occurred between 0.1 and 3 µM, and correlated with the BrdUrd LI for the untreated control (r² = 0.37; P < 0.01). It is interesting that > 95% of apoptotic cells were BrdUrd labeled, whereas not all BrdUrd-labeled cells were apoptotic. To investigate the basis of the variable tumor response to taxol, we determined the expression of multidrug resistance P-glycoprotein (Pgp), p53, and bcl-2 proteins, using immunohistochemical staining and Western blot analysis. Eleven (50%), 10 (45%), and 7 (32%) tumors expressed Pgp, p53, and bcl-2, respectively. Patients with Pgp-positive tumors showed a higher number of affected lymph nodes than those with Pgp-negative tumors (P < 0.05). Compared with moderately and well differentiated tumors, the poorly differentiated tumors expressed p53 and Pgp more frequently and showed a lower maximum inhibition of DNA synthesis and a higher apoptotic fraction after taxol treatment (P < 0.05 in both cases). Pgp expression correlated differently with taxol-induced inhibition of DNA synthesis than with apoptosis; Pgp-positive tumors showed a significantly higher E_max (63%) and IC₃₀ (4.2 µM) but also a higher apoptotic index (17%) than Pgp-negative tumors (E_max, 36%; IC₃₀, 0.3 µM; and apoptotic index, 6%; P < 0.05 for all cases). p53 and bcl-2 expression did not correlate with taxol-induced inhibition of DNA synthesis or apoptosis. The data indicate that taxol acts through apoptosis and inhibition of proliferation in human head and neck cancer. Pgp overexpression appears to protect cells from the antiproliferative effect of taxol but correlates with a higher apoptosis.

¹ This study was supported in part by Research Grant R37CA49816 and Research Career Development Award K04CA01497 from the National Cancer Institute, NIH, Department of Health and Human Services, and a grant from Bristol-Myers Squibb. The Ohio State University Comprehensive Cancer Center Tissue Procurement Service was supported in part by Grant P30CA16058 from the National Cancer Institute, NIH, Department of Health and Human Services.

² To whom requests for reprints should be addressed, at College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210. Phone: (614) 292-4244; Fax: (614) 688-3223.

Received 12/21/95. Accepted 3/18/96.

This article has been cited by other articles:

				D. Lu, M. G. Wientjes, Z. Lu, and J. L.-S. Au Tumor Priming Enhances Delivery and Efficacy of Nanomedicines J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 80 - 88. [Abstract] [Full Text] [PDF]

				S. Song, B. Yu, Y. Wei, M. G. Wientjes, and J. L.-S. Au Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naive and Paclitaxel-Pretreated Human Breast Xenograft Tumors Clin. Cancer Res., September 15, 2004; 10(18): 6058 - 6065. [Abstract] [Full Text] [PDF]

				Y. Mo, Y. Gan, S. Song, J. Johnston, X. Xiao, M. G. Wientjes, and J. L-S. Au Simultaneous Targeting of Telomeres and Telomerase as a Cancer Therapeutic Approach Cancer Res., February 1, 2003; 63(3): 579 - 585. [Abstract] [Full Text] [PDF]

				S. C. Coleman, Z. A. Stewart, T. A. Day, J. L. Netterville, B. B. Burkey, and J. A. Pietenpol Analysis of Cell-Cycle Checkpoint Pathways in Head and Neck Cancer Cell Lines: Implications for Therapeutic Strategies Arch Otolaryngol Head Neck Surg, February 1, 2002; 128(2): 167 - 176. [Abstract] [Full Text] [PDF]

				Y. Zhang, S. Song, F. Yang, J. L.-S. Au, and M. G. Wientjes Nontoxic Doses of Suramin Enhance Activity of Doxorubicin in Prostate Tumors J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 426 - 433. [Abstract] [Full Text] [PDF]

				S. Song, M. G. Wientjes, C. Walsh, and J. L-S. Au Nontoxic Doses of Suramin Enhance Activity of Paclitaxel against Lung Metastases Cancer Res., August 1, 2001; 61(16): 6145 - 6150. [Abstract] [Full Text] [PDF]

				S. H. Jang, M. G. Wientjes, and J. L.-S. Au Enhancement of Paclitaxel Delivery to Solid Tumors by Apoptosis-Inducing Pretreatment: Effect of Treatment Schedule J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1035 - 1042. [Abstract] [Full Text]

				S. M. Poelman, M. O. Adeyanju, M.-A. Robertson, W. M. Recant, T. Karrison, G. F. Fleming, O. I. Olopade, and S. D. Conzen Human Breast Cancer Susceptibility to Paclitaxel Therapy Is Independent of Bcl-2 Expression Clin. Cancer Res., October 1, 2000; 6(10): 4043 - 4048. [Abstract] [Full Text]

				D. Schrijvers and J.B. Vermorken Role of Taxoids in Head and Neck Cancer Oncologist, June 1, 2000; 5(3): 199 - 208. [Abstract] [Full Text]

				J. C. Grecula, D. E. Schuller, C. A. Rhoades, J. L.-S. Au, S. Nag, C. J. Bauer, A. Agrawal, R. Martinez-Monge, A. Johnson, D. Young, et al. Intensification Regimen 2 for Advanced Head and Neck Squamous Cell Carcinomas Arch Otolaryngol Head Neck Surg, December 1, 1999; 125(12): 1313 - 1318. [Abstract] [Full Text] [PDF]

				H.-J. Kuh, S. H. Jang, M. G. Wientjes, J. R. Weaver, and J. L.-S. Au Determinants of Paclitaxel Penetration and Accumulation in Human Solid Tumor J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 871 - 880. [Abstract] [Full Text]

				Y. F. Lam, C. J. Chan, and J. G Kuhn Review : Pharmacokinetics and pharmacodynamics of the taxanes Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 76 - 93. [Abstract] [PDF]